Literature DB >> 114397

Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.

M D'Incalci, T Facchinetti, G Bolis, C Mangioni, L Morasca.   

Abstract

We have studied Cyclophosphamide (Cy) pharmacokinetics in 9 patients after their first intravenous dose of 100 mg, and in 9 patients after 6--13 months of continual treatment with the same dose every day. The half-life of Cy was shorter (p less than 0.05) in the latter group, the Co was greater (less than 0.01) and the Vd was clearly less (p less than 0.01). The AUC was unchanged.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 114397     DOI： 10.1007/BF03189405

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


  13 in total

1.  Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.

Authors:  G E FOLEY; O M FRIEDMAN; B P DROLET
Journal:  Cancer Res       Date:  1961-01       Impact factor: 12.701

2.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

Authors:  N Brock
Journal:  Cancer Treat Rep       Date:  1976-04

3.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

4.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors:  J L Cohen; J Y Jao
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

5.  The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Authors:  H T Mouridsen; O Faber; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-08

6.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

7.  Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite.

Authors:  D L Hill; W R Laster; R F Struck
Journal:  Cancer Res       Date:  1972-04       Impact factor: 12.701

8.  Drug metabolism after repeated treatments with cytotoxic agents.

Authors:  M G Donelli; S Garattini
Journal:  Eur J Cancer       Date:  1971-08       Impact factor: 9.162

9.  Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen--phosphorus-selective detector.

Authors:  T Facchinetti; M D'Incalci; G Martelli; L Cantoni; G Belvedere; M Salmona
Journal:  J Chromatogr       Date:  1978-03-01

10.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
View more
  1 in total

1.  Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Authors:  Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana
Journal:  Clin Cancer Res       Date:  2012-11-08       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.